Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus recommendation of “Hold” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Walleye Capital LLC acquired a new position in shares of Agenus during the third quarter worth about $1,003,000. Federated Hermes Inc. acquired a new stake in shares of Agenus in the second quarter valued at approximately $1,921,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Agenus in the second quarter worth $1,050,000. BNP Paribas Financial Markets grew its position in Agenus by 2,271.5% in the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Agenus in the 2nd quarter valued at $614,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Stock Down 4.2 %

Agenus stock opened at $3.40 on Friday. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The stock has a 50-day simple moving average of $3.22 and a 200 day simple moving average of $5.83. The stock has a market capitalization of $79.76 million, a price-to-earnings ratio of -0.30 and a beta of 1.27.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.